1,003 results match your criteria Heart Failure Reviews[Journal]


Authors' response to the letter: Takotsubo syndrome: a neurocardiac syndrome inside the autonomic nervous system.

Heart Fail Rev 2019 Apr 16. Epub 2019 Apr 16.

Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, 1b Banacha Street, 02-097, Warsaw, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09789-yDOI Listing

Speckle tracking echocardiography in cardiac amyloidosis.

Heart Fail Rev 2019 Apr 15. Epub 2019 Apr 15.

Department of Cardiovascular Diseases, University of Siena, Siena, Italy.

Speckle tracking echocardiography is an imaging method, based on analysis of 2D echocardiographic images, that is useful in providing information on tissue deformation in different cardiac diseases. Cardiac amyloidosis is a complex pathological entity that can be confused with other causes responsible for cardiac hypertrophy, and for this reason, it can be misdiagnosed, especially in the early stages. Cardiac magnetic resonance and endomyocardial biopsy are reference methods for specific diagnosis, but their use is limited by a number of factors, both of a logistical and technical nature. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-019-09796-z
Publisher Site
http://dx.doi.org/10.1007/s10741-019-09796-zDOI Listing
April 2019
1 Read

Right ventricular function after cardiac surgery: the diagnostic and prognostic role of echocardiography.

Heart Fail Rev 2019 Apr 13. Epub 2019 Apr 13.

Department of Cardiovascular Diseases, University of Siena, Siena, Italy.

Cardiac surgical techniques and circulatory supports have strongly evolved in the last years. Right ventricular (RV) function during the post-operatory period is still subject of study, although its relevant prognostic impact has been variably described in different papers. RV post-surgical dysfunction's underlying mechanisms are still not clear and include a different hypothesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09785-2DOI Listing

Targeting transcriptional machinery to inhibit enhancer-driven gene expression in heart failure.

Heart Fail Rev 2019 Apr 11. Epub 2019 Apr 11.

Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, 169 Newton Rd., 4332 PBDB, Iowa City, IA, 52242, USA.

Pathological cardiac remodeling is induced through multiple mechanisms that include neurohumoral and biomechanical stress resulting in transcriptional alterations that ultimately become maladaptive and lead to the development of heart failure (HF). Although cardiac transcriptional remodeling is mediated by the activation of numerous signaling pathways that converge on a limited number of transcription factors (TFs) that promote hypertrophy (pro-hypertrophic TFs), the current therapeutic approach to prevent HF utilizes pharmacological inhibitors that largely target specific receptors that are activated in response to pathological stimuli. Thus, there is limited efficacy with the current pharmacological approaches to inhibit transcriptional remodeling associated with the development of HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09792-3DOI Listing

Advanced heart failure: non-pharmacological approach.

Heart Fail Rev 2019 Apr 10. Epub 2019 Apr 10.

Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122, Foggia, Italy.

Patients with advanced heart failure have poor prognosis despite traditional pharmacological therapies. The early identification of these subjects would allow them to be addressed on time in dedicated centers to select patients eligible for heart transplantation or ventricular assistance. In this article we will report the current management of these patients based on latest international guidelines, underlining some critical aspects, with reference to future perspectives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09786-1DOI Listing
April 2019
1 Read

Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review.

Heart Fail Rev 2019 Apr 5. Epub 2019 Apr 5.

'Grigore T. Popa' University of Medicine, Iasi, Romania.

Heart failure with preserved ejection fraction (HFpEF) is a common disorder generating high mortality and important morbidity prevalence, with a very limited medical treatment available. Studies have shown that the pathophysiological hallmark of this condition is an elevated left intra-atrial pressure (LAP), exertional dyspnea being its clinical manifestation. The increasing pressure from LA is not based on volume overload (such as in heart failure with reduced ejection fraction) but on a diastolic left ventricular (LV) dysfunction combined with an inter-atrial dyssynchrony mimicking a pseudo-pacemaker syndrome. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-019-09787-0
Publisher Site
http://dx.doi.org/10.1007/s10741-019-09787-0DOI Listing
April 2019
5 Reads

Pharmacological management of cardiac cachexia: a review of potential therapy options.

Heart Fail Rev 2019 Mar 28. Epub 2019 Mar 28.

UF Health Shands Hospital, 1600 SW Archer Rd., Gainesville, FL, 32608, USA.

Cardiac cachexia is a syndrome of progressive skeletal muscle and fat loss affecting a significant number of congestive heart failure patients. With the potential detrimental effects of cardiac muscle wasting, greater attention is needed to understanding the prevention and treatment of the condition. Potential therapeutic approaches are aimed at the various mechanisms for the pathogenesis of cardiac cachexia including neurohormonal abnormalities, immune activation and inflammation, metabolic hormonal imbalance, and gastrointestinal abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09784-3DOI Listing
March 2019
1 Read

Nutrition intervention in heart failure: should consumption of the DASH eating pattern be recommended to improve outcomes?

Heart Fail Rev 2019 Mar 28. Epub 2019 Mar 28.

Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Augusta, GA, USA.

Heart failure (HF) is a chronic, systemic disorder that presents a serious and growing public health problem due to its high prevalence, mortality, and cost of care. Due to the aging of the population and medical advances that prolong the life of HF patients, more effective, widespread strategies for improved HF management in this rapidly growing patient population are needed. While the prevalence of malnutrition in HF patients has been well characterized, evidence is limited regarding the effects of specific macro- and micronutrient deficiencies on HF outcomes and their interaction with other aspects of HF management, including pharmacotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09781-6DOI Listing

Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.

Heart Fail Rev 2019 Mar 22. Epub 2019 Mar 22.

Health Economics Group, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7JT, UK.

The accurate measurement of health-related quality of life (HRQoL) and the value of improving it for patients are essential for deriving quality-adjusted life years (QALYs) to inform treatment choice and resource allocation. The objective of this review was to identify and describe the approaches used to measure and value change in HRQoL in trial-based economic evaluations of heart failure interventions which derive QALYs as an outcome. Three databases (PubMed, CINAHL, Cochrane) were systematically searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09780-7DOI Listing

Surgical and physiological challenges in the development of left and right heart failure in rat models.

Heart Fail Rev 2019 Mar 22. Epub 2019 Mar 22.

Cardiovascular Research Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave., Box 1030, New York, NY, 10029-6574, USA.

Rodent surgical animal models of heart failure (HF) are critically important for understanding the proof of principle of the cellular alterations underlying the development of the disease as well as evaluating therapeutics. Robust, reproducible rodent models are a prerequisite to the development of pharmacological and molecular strategies for the treatment of HF in patients. Due to the absence of standardized guidelines regarding surgical technique and clear criteria for HF progression in rats, objectivity is compromised. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09783-4DOI Listing
March 2019
1 Read
3.787 Impact Factor

The long non-coding road to endogenous cardiac regeneration.

Heart Fail Rev 2019 Mar 21. Epub 2019 Mar 21.

School of Medicine, New Giza University (NGU), Giza, Egypt.

The human heart has a markedly low regenerative capacity, leaving patients who suffered from cardiac insults vulnerable to heart failure. The inability to regenerate lost myocardium is accompanied by extensive remodeling that leads to further deterioration in cardiac functions and structure. Although adult mammals seem to lack the ability to regenerate, some lower vertebrates have a cardio-regenerative potential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09782-5DOI Listing

READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials.

Heart Fail Rev 2019 Mar 14. Epub 2019 Mar 14.

Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

The majority of patients with chronic heart failure (HF) receive long-term treatment with loop diuretics. The comparative effectiveness of different loop diuretics is unknown. We searched PubMed, clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09771-8DOI Listing
March 2019
3 Reads

Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Heart Fail Rev 2019 Mar 9. Epub 2019 Mar 9.

2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon Hospital, Rimini 1, 12462, Haidari, Greece.

Hypertrophic cardiomyopathy (HCM) represents a phenotype of left ventricular hypertrophy unexplained by abnormal loading conditions. The definition is based on clinical criteria; however, there are numerous underlying etiologic factors. The MOGE(S) classification provides a standardized approach for multimodal characterization of HCM. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-019-09775-4
Publisher Site
http://dx.doi.org/10.1007/s10741-019-09775-4DOI Listing
March 2019
3 Reads

Right ventricular mechanical pattern in health and disease: beyond longitudinal shortening.

Heart Fail Rev 2019 Mar 9. Epub 2019 Mar 9.

Semmelweis University Heart and Vascular Center, Városmajor St. 68, Budapest, H-1122, Hungary.

Right ventricular (RV) function has proven to be a prognostic factor in heart failure with reduced and preserved ejection fraction and in pulmonary hypertension. RV function is also a cornerstone in the management of novel clinical issues, such as mechanical circulatory support devices or grown-up congenital heart disease patients. Despite the notable amount of circumferentially oriented myofibers in the subepicardial layer of the RV myocardium, the non-longitudinal motion directions are often neglected in the everyday assessment of RV function by echocardiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09778-1DOI Listing

Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015.

Heart Fail Rev 2019 Mar 8. Epub 2019 Mar 8.

Medical School Twente, Medisch Spectrum Twente, Enschede, the Netherlands.

Prescriber adherence to guideline-recommended medication in patients with heart failure (HF) in clinical practice is suboptimal. We analyzed how evolving guideline recommendations influenced medication profiles after a first HF hospitalization. We extracted medication profiles from the Dutch PHARMO Database Network for 22,476 patients with a diagnosis of HF at hospital discharge between 2001 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09777-2DOI Listing

Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases.

Heart Fail Rev 2019 Mar 4. Epub 2019 Mar 4.

Onassis Cardiac Surgery Center, 50 Esperou Street, 175-61 P. Faliro, Athens, Greece.

Autoimmune rheumatic diseases (ARDs) affect 8% of the population, and approximately 78% of them are women. Cardiovascular disease (CVD) in ARDs encompasses different pathophysiologic processes, such as endothelial dysfunction, myocardial/vascular inflammation and accelerated atherosclerosis with silent clinical presentation, leading to heart failure (HF), usually with preserved ejection fraction. Echocardiography and cardiovascular magnetic resonance (CMR) are the two most commonly used noninvasive imaging modalities for the evaluation of HF in patients with ARDs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-019-09779-0
Publisher Site
http://dx.doi.org/10.1007/s10741-019-09779-0DOI Listing
March 2019
8 Reads

Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy.

Heart Fail Rev 2019 Feb 26. Epub 2019 Feb 26.

Department of Medical and Surgery Sciences, University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy.

Takotsubo syndrome (TTS) can be induced by a large variety of physical/emotional triggers; several cases, however, are related to either an overt or occult malignancy, as shown in retrospective studies and case reports. The aim of this study was therefore to evaluate the clinical outcome of patients with TTS and cancer in a meta-analysis study. In June 2018, a Pubmed systematic research was conducted for studies assessing outcome in patients with TTS and cancer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-019-09773-6
Publisher Site
http://dx.doi.org/10.1007/s10741-019-09773-6DOI Listing
February 2019
4 Reads

Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.

Heart Fail Rev 2019 Feb 21. Epub 2019 Feb 21.

Mid-German Heart Center, Department of Internal Medicine III (KIM-III), Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Strasse 40, D-06120, Halle (Saale), Germany.

Amyloidosis is caused by extracellular deposition of insoluble abnormal fibrils constituted by misfolded proteins, which can modify tissue anatomy and hinder the function of multiple organs including the heart. Amyloidosis that can affect the heart includes mostly systemic amyloidosis (amyloid light chain, AL) and transthyretin amyloidosis (ATTR). The latter can be acquired in elderly patients (ATTRwt), or be inherited in younger individuals (ATTRm). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09776-3DOI Listing
February 2019
1 Read

Personalized physiology-guided resuscitation in highly monitored patients with cardiac arrest-the PERSEUS resuscitation protocol.

Heart Fail Rev 2019 Feb 11. Epub 2019 Feb 11.

School of Medicine, European University Cyprus, Nicosia, Cyprus.

Resuscitation guidelines remain uniform across all cardiac arrest patients, focusing on the delivery of chest compressions to a standardized rate and depth and algorithmic vasopressor dosing. However, individualizing resuscitation to the appropriate hemodynamic and ventilatory goals rather than a standard "one-size-fits-all" treatment seems a promising new therapeutic strategy. In this article, we present a new physiology-guided treatment strategy to titrate the resuscitation efforts to patient's physiologic response after cardiac arrest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09772-7DOI Listing
February 2019
2 Reads

The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.

Heart Fail Rev 2019 Feb 2. Epub 2019 Feb 2.

Department of Biochemistry and Molecular Biology, University of Bielsko-Biala, Faculty of Health Sciences, Willowa St. 2, 43-309, Bielsko-Biała, Poland.

Myocardial infarction and post-infarction left ventricular remodelling involve a high risk of morbidity and mortality. For this reason, ongoing research is being conducted in order to learn the mechanisms of unfavourable left ventricular remodelling following a myocardial infarction. New biomarkers are also being sought that would allow for early identification of patients with a high risk of post-infarction remodelling and dysfunction of the left ventricle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09770-9DOI Listing
February 2019

Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy.

Heart Fail Rev 2019 Jan 23. Epub 2019 Jan 23.

Werlhof-Institut, Hannover, Germany.

Accumulation of macrophages within the artery wall is an eminent feature of atherosclerotic plaques. Macrophages are influenced by various plaque microenvironmental stimuli, such as oxidized lipids, cytokines, and senescent erythrocytes, and thereby polarize into two main phenotypes called proinflammatory M1 and anti-inflammatory M2 macrophages. In the hemorrhagic zones of atheroma, upon exposure to iron, sequestration of iron by M1 macrophages results in an uncontrolled proinflammatory phenotype impairing wound healing, while M2 macrophages phagocytose both apoptotic cells and senescent erythrocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-09764-zDOI Listing
January 2019
3 Reads
3.787 Impact Factor

Experimental models of cardiac physiology and pathology.

Heart Fail Rev 2019 Jan 22. Epub 2019 Jan 22.

Icahn School of Medicine at Mount Sinai, New York, USA.

Experimental models of cardiac disease play a key role in understanding the pathophysiology of the disease and developing new therapies. The features of the experimental models should reflect the clinical phenotype, which can have a wide spectrum of underlying mechanisms. We review characteristics of commonly used experimental models of cardiac physiology and pathophysiology in all translational steps including in vitro, small animal, and large animal models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09769-2DOI Listing
January 2019
1 Read

Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.

Heart Fail Rev 2019 Jan 15. Epub 2019 Jan 15.

Department of Haematology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 7505, South Africa.

Blood pressure (BP) is a complex trait that is regulated by multiple physiological pathways and include but is not limited to extracellular fluid volume homeostasis, cardiac contractility, and vascular tone through renal, neural, or endocrine systems. Uncontrolled hypertension (HTN) has been associated with an increased mortality risk. Therefore, understanding the genetics that underpins and influence BP regulation will have a major impact on public health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-09765-yDOI Listing
January 2019
2 Reads

Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Heart Fail Rev 2019 Jan 7. Epub 2019 Jan 7.

Department of Health Policy, The London School of Economics and Political Science, London, UK.

Heart failure with preserved ejection fraction (HFpEF) is a disease with limited evidence-based treatment options. Mineralocorticoid receptor antagonists (MRA) offer benefit in heart failure with reduced ejection fraction (HFrEF), but their impact in HFpEF remains unclear. We therefore evaluated the effect of MRA on echocardiographic, functional, and systemic parameters in patients with HFpEF by a systematic review and meta-analysis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9758-0
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9758-0DOI Listing
January 2019
24 Reads

Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Heart Fail Rev 2019 Jan 8. Epub 2019 Jan 8.

Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany.

Treatment of left ventricular outflow tract (LVOT) obstruction in hypertrophic obstructive cardiomyopathy (HOCM) with septal reduction, either with myectomy or alcohol septal ablation, is aiming to reduce the LVOT gradient and improve symptoms in patients who are refractory to or do not tolerate medical treatment. Apart from contributing to the evolution to heart failure, LVOT obstruction is considered a risk factor for sudden cardiac death (SCD). Both septal reduction treatments have been proven effective in reducing symptoms and seem to improve survival, which has been shown equal to the expected in the normal population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-09767-w
Publisher Site
http://dx.doi.org/10.1007/s10741-018-09767-wDOI Listing
January 2019
20 Reads

Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review.

Heart Fail Rev 2019 Jan 8. Epub 2019 Jan 8.

Division of Cardiovascular Medicine, St. Elizabeth's Medical Center/ Tufts University School of Medicine, Brighton, MA, 02135, USA.

The prevalence of heart failure (HF) is on the rise. By 2030, over eight million Americans (46% increase from current prevalence) will have heart failure. In the USA, approximately 30 billion dollars is spent annually on heart failure and this number will likely double in 2030. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9760-6DOI Listing
January 2019
1 Read

Left ventricular noncompaction, morphological, and clinical features for an integrated diagnosis.

Heart Fail Rev 2019 Jan 5. Epub 2019 Jan 5.

Cardiovascular Department, Cardiomyopathy Center, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.

The presence of myocardial noncompaction (NC), regardless of the criterion used, does not identify cardiomyopathy per se. The distinction between a morphological variant and the presence of an NC cardiomyopathy is challenging. However, thanks to larger cohorts of patients and longer periods of follow-up, better clinical characterization and prognostic evaluation are becoming available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9763-3DOI Listing
January 2019
2 Reads

Current animal models for the study of congestion in heart failure: an overview.

Heart Fail Rev 2019 Jan 5. Epub 2019 Jan 5.

BIOMED - Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium.

Congestion (i.e., backward failure) is an important culprit mechanism driving disease progression in heart failure. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9762-4
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9762-4DOI Listing
January 2019
5 Reads

Obesity and heart failure with preserved ejection fraction: a paradox or something else?

Heart Fail Rev 2019 Jan 5. Epub 2019 Jan 5.

Clinical Research Unit, University of Milan-Bicocca and Istituto Auxologico Italiano, Viale della Resistenza 23, 20036, Meda, Italy.

Obesity represents one of the most common comorbidities in patients with heart failure and preserved ejection fraction (HFpEF). Studies have shown that obesity is not only a comorbidity, but it could also be an important risk factor for HFpEF development. The mechanisms that connect obesity and HFpEF vary from obesity-induced hemodynamic changes to important biohumoral systems such as adipocitokines, renin-angiotensin-aldosterone and sympathetic nervous systems, natriuretic peptide, and oxidative stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-09766-xDOI Listing
January 2019
1 Read

Comparison of survival for cardiac resynchronization therapy in atrial fibrillation patients with or without atrio-ventricular junction ablation and patients in sinus rhythm: a systematic review and network meta-analysis.

Heart Fail Rev 2019 Jan 4. Epub 2019 Jan 4.

Department of Cardiology, the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Xueyuanxi Road, No. 109, Wenzhou, 325000, Zhejiang, China.

Cardiac resynchronization therapy (CRT) has been established to improve prognosis for patients with heart failure and SR. Whether the benefit observed with CRT on survival was similar in AF patients receiving atrio-ventricular junction ablation (AVJA) or not and patients in SR remains uncertain. The primary purpose of this study was to comprehensively evaluate the impact of CRT on the outcome of survival in atrial fibrillation (AF) patients with or without AVJA and patients in sinus rhythm (SR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9761-5DOI Listing
January 2019
2 Reads

Practical guidance on the use of sacubitril/valsartan for heart failure.

Heart Fail Rev 2019 Mar;24(2):167-176

Department of Medicine, Division of Cardiology, Washington University in St Louis, St Louis, MO, USA.

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has been recommended in clinical practice guidelines to reduce morbidity and mortality in patients with chronic, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This review provides an overview of ARNI therapy, proposes strategies to improve the implementation of sacubitril/valsartan in clinical practice, and provides clinicians with evidence-based, practical guidance on the use of sacubitril/valsartan in patients with HFrEF. Despite evidence demonstrating the benefits of ARNI therapy over standard of care, only a fraction of eligible patients takes sacubitril/valsartan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9757-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394573PMC
March 2019
7 Reads

Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.

Heart Fail Rev 2018 Dec 6. Epub 2018 Dec 6.

Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.

Some randomized controlled trials (RCTs) have tested the efficacy of beta-blockers as prophylactic agents on cancer therapy-induced cardiotoxicity; however, the quality of this evidence remains undetermined. This systematic review and meta-analysis study aims to evaluate the prophylactic effects of beta-blockers, especially carvedilol, on chemotherapy-induced cardiotoxicity. RCTs were identified by searching the MEDLINE (PubMed), Embase (OvidSP), Cochrane CENTRAL (OvidSP), etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9755-3DOI Listing
December 2018
1 Read
3.787 Impact Factor

Wnt/β-catenin in ischemic myocardium: interactions and signaling pathways as a therapeutic target.

Heart Fail Rev 2018 Dec 12. Epub 2018 Dec 12.

Department of biochemistry and hematology, faculty of medicine, Semnan University of Medical Sciences, Semnan, Iran.

Cardiovascular disease (CVD) is still a factor of mortality in the whole world. Through canonical and noncanonical pathways and with different receptors, the Wnt/β-catenin signaling pathway plays an essential role in response to heart injuries. Wnt regulates the mobilization and proliferation of cells in endothelium and epicardium in an infarcted heart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9759-zDOI Listing
December 2018
1 Read

Improvement of hyponatremia is associated with lower mortality risk in patients with acute decompensated heart failure: a meta-analysis of cohort studies.

Heart Fail Rev 2019 Mar;24(2):209-217

Department of Interventional Medicine, Weihai Municipal Hospital, Weihai, 264200, China.

Hyponatremia at admission is predictive of poor prognosis in patients with acute decompensated heart failure (ADHF). We performed a meta-analysis of cohort studies to evaluate whether improvement of hyponatremia is associated with improved survival in patients with ADHF and hyponatremia. Relevant studies were identified through systematic search of PubMed and Embase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9753-5DOI Listing
March 2019
3 Reads

Mitochondrial membrane transporters and metabolic switch in heart failure.

Heart Fail Rev 2019 Mar;24(2):255-267

Cardiovascular Diseases and Diabetes Biology group, Rajiv Gandhi Centre for Biotechnology (RGCB), Poojappura, Thycaud Post, Trivandrum, Kerala, 695014, India.

Mitochondrial dysfunction is widely recognized as a major factor for the progression of cardiac failure. Mitochondrial uptake of metabolic substrates and their utilization for ATP synthesis, electron transport chain activity, reactive oxygen species levels, ion homeostasis, mitochondrial biogenesis, and dynamics as well as levels of reactive oxygen species in the mitochondria are key factors which regulate mitochondrial function in the normal heart. Alterations in these functions contribute to adverse outcomes in heart failure. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9756-2
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9756-2DOI Listing
March 2019
10 Reads

Updates in heart failure 30-day readmission prevention.

Heart Fail Rev 2019 Mar;24(2):177-187

University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06032, USA.

Heart failure (HF) and HF 30-day readmission rates have been a major focus of efforts to reduce health care cost in the recent era. Since the implementation of the Affordable Care Act (ACA) in 2012 and the Hospital Readmission Reduction Program (HRRP), concerted efforts have focused on reduction of 30-day HF readmissions and other admission diagnoses targeted by the HRRP. Hospitals and organizations have instituted wide-ranging programs to reduce short-term readmissions, but the data supporting these programs is often mixed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9754-4DOI Listing
March 2019
1 Read

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Heart Fail Rev 2019 Mar;24(2):189-197

Division of Cardiology, Lehigh Valley Health Network, 1200 S. Cedar Crest Blvd, Allentown, PA, 18103, USA.

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9752-6
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9752-6DOI Listing
March 2019
32 Reads
3.790 Impact Factor

Cell-based therapies for the treatment of myocardial infarction: lessons from cardiac regeneration and repair mechanisms in non-human vertebrates.

Heart Fail Rev 2019 Jan;24(1):133-142

Department of Animal Biology, Faculty of Sciences, University of Málaga, Instituto Malagueño de Biomedicina (IBIMA), Campus de Teatinos s/n, 29071, Málaga, Spain.

Ischemic cardiomyopathy is the cardiovascular condition with the highest impact on the Western population. In mammals (humans included), prolonged ischemia in the ventricular walls causes the death of cardiomyocytes (myocardial infarction, MI). The loss of myocardial mass is soon compensated by the formation of a reparative, non-contractile fibrotic scar that ultimately affects heart performance. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9750-8
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9750-8DOI Listing
January 2019
14 Reads

The use of hospital-based services by heart failure patients in the last year of life: a discussion paper.

Heart Fail Rev 2019 Mar;24(2):199-207

School of Nursing and Midwifery, Western Sydney University, Locked Bag 1797, Penrith, NSW, 2751, Australia.

Individuals with chronic heart failure have high utilisation of hospital-related services towards the end of life and receive treatments that provide symptom relief without improving life expectancy. The aim of this discussion paper is to determine chronic heart failure patients' use of acute hospital-based services in their last year of life and to discuss the potential for palliative care to reduce service utilisation. A systematic search of the literature was conducted. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9751-7
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9751-7DOI Listing
March 2019
14 Reads

The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis.

Heart Fail Rev 2019 Jan;24(1):109-114

Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Influenza infection is associated with increased risk for mortality and hospitalization in heart failure patients. Although there are no published randomized controlled trials examining the effect of influenza vaccination on clinical outcomes in heart failure patients, the effect has been examined in observational cohort studies. Nevertheless, results are inconsistent due partly to limited power with small sample sizes and use of different definitions of outcomes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9736-6
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9736-6DOI Listing
January 2019
33 Reads
3.790 Impact Factor

Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.

Heart Fail Rev 2019 Mar;24(2):279-299

Center for Biological Sciences, Department of Biochemistry, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Tamil Nadu, 637215, India.

Abstarct: Diabetic complications are among the largely exigent health problems currently. Cardiovascular complications, including diabetic cardiomyopathy (DCM), account for more than 80% of diabetic deaths. Investigators are exploring new therapeutic targets to slow or abate diabetes because of the growing occurrence and augmented risk of deaths due to its complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9749-1DOI Listing
March 2019
2 Reads
3.787 Impact Factor

Takotsubo syndrome: a neurocardiac syndrome inside the autonomic nervous system.

Heart Fail Rev 2019 Mar;24(2):227

Cardiovascular and Thoracic Department, University Hospital of Verona, P. Stefani 1, 37126, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9748-2DOI Listing
March 2019
1 Read

Chronic heart failure: a disease of the brain.

Heart Fail Rev 2019 Mar;24(2):301-307

Halberg Chronobiology Center, University of Minnesota Medical School, Minneapolis, USA.

The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9747-3
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9747-3DOI Listing
March 2019
10 Reads

Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Heart Fail Rev 2019 Mar;24(2):245-254

Cardiology Department, Benha Faculty of Medicine, Benha University, Benha, 13518, Egypt.

Heart failure with reduced ejection fraction (HFrEF) represents a significant public health burden associated with incremental health care costs. Given the limitations associated with pharmacological autonomic regulation therapy (ART), device-based autonomic neuromodulation is on the horizon now for ART in those patients. This systematic review aimed primarily to determine the effect of ART by devices on functional status and quality of life (QOL) in patients with HFrEF. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9745-5
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9745-5DOI Listing
March 2019
6 Reads
3.790 Impact Factor

Left ventricular assist device recovery: does duration of mechanical support matter?

Heart Fail Rev 2019 Mar;24(2):237-244

University of Miami, Miller School of Medicine, Miami, FL, USA.

Heart failure is a widespread condition in the United States that is predicted to significantly increase in prevalence in the next decade. Many heart failure patients are given a left ventricular assist device (LVAD) while they wait for a heart transplant, while those that are not able to undergo a heart transplant may be given an LVAD permanently. However, past studies have observed a small subset of heart failure patients that recovered cardiac function of their native heart after being placed on an LVAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9744-6DOI Listing
March 2019
1 Read

Intercalated discs: cellular adhesion and signaling in heart health and diseases.

Heart Fail Rev 2019 Jan;24(1):115-132

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Intercalated discs (ICDs) are highly orchestrated structures that connect neighboring cardiomyocytes in the heart. Three major complexes are distinguished in ICD: desmosome, adherens junction (AJ), and gap junction (GJ). Desmosomes are major cell adhesion junctions that anchor cell membrane to the intermediate filament network; AJs connect the actin cytoskeleton of adjacent cells; and gap junctions metabolically and electrically connect the cytoplasm of adjacent cardiomyocytes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9743-7
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9743-7DOI Listing
January 2019
7 Reads

Implantable devices to monitor patients with heart failure.

Heart Fail Rev 2018 11;23(6):849-857

Attikon General University Hospital, 1 Rimini Str, 122 43, Chaidari, Greece.

Reducing heart failure hospitalizations represents a major challenge for modern clinicians. Early detection of congestion plays a key role in disease management strategy. Apart from traditional methods (patient reporting symptoms, body weight monitoring), novel home-care strategies allow guided adjustments in medical therapy through telemonitoring embedded in cardiac electronic implantable devices or through stand-alone diagnostic devices for hemodynamic monitoring. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9742-8
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9742-8DOI Listing
November 2018
21 Reads

Structural and functional abnormalities in iron-depleted heart.

Heart Fail Rev 2019 Mar;24(2):269-277

Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.

Iron deficiency (ID) is a common and ominous comorbidity in heart failure (HF) and predicts worse outcomes, independently of the presence of anaemia. Accumulated data from animal models of systemic ID suggest that ID is associated with several functional and structural abnormalities of the heart. However, the exact role of myocardial iron deficiency irrespective of systemic ID and/or anaemia has been elusive. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10741-018-9738-4
Publisher Site
http://dx.doi.org/10.1007/s10741-018-9738-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394598PMC
March 2019
2 Reads

Creation of a restrictive atrial left-to-right shunt: a novel treatment for heart failure.

Authors:
R De Rosa D Schranz

Heart Fail Rev 2018 11;23(6):841-847

Hessen Pediatric Heart Center Giessen & Frankfurt, Goethe University Frankfurt, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany.

Elevated left atrial (LA) filling pressures are associated with poor prognosis in patients with heart failure (HF). Recent evidences have shown that, in this setting, the presence of restrictive small atrial defect may protect from an extreme increase in LA pressure and prevent consecutive pulmonary congestion and acute decompensation, without the expense of an unfavourable significant left-to-right shunt. Therefore, decompression of LA by creating a unidirectional but restrictive left-to-right interatrial shunt has been emerging as a new therapeutic strategy in patients suffering from both HF with preserved and reduced ejection fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9741-9DOI Listing
November 2018
16 Reads

Cardiac resynchronization therapy and outcomes in patients with left ventricular assist devices: a systematic review and meta-analysis.

Heart Fail Rev 2019 Mar;24(2):229-236

Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

The impact of cardiac resynchronization therapy (CRT) on clinical outcome in patients with a continuous-flow left ventricular assist device (LVAD) is currently not well understood. We conducted a systematic literature review and meta-analysis with an intention to summarize all published clinical evidence. We searched MEDLINE and EMBASE databases through March 2018 for studies that compared the outcomes in patients with LVAD and CRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-018-9740-xDOI Listing
March 2019
3 Reads